<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089539</url>
  </required_header>
  <id_info>
    <org_study_id>2021-10-21</org_study_id>
    <nct_id>NCT05089539</nct_id>
  </id_info>
  <brief_title>The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF</brief_title>
  <acronym>ARNICFH</acronym>
  <official_title>The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effectively therapeutic approaches for Heart failure with preserved ejection fraction&#xD;
      (HFpEF) remain limited. The PARAGON-HF trial found that Angiotensin Receptor-Neprilysin&#xD;
      Inhibition (ARNI) has potential benefits for the management of HFpEF. Nevertheless, the role&#xD;
      of ARNI in cardiac fibrosis in HFpEF are still unclear. We will conduct a prospective&#xD;
      randomized controlled trial to evaluate the effect of ARNI on cardiac fibrosis in patients&#xD;
      with HFpEF by cardiac magnetic resonance (CMR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure with preserved ejection fraction (HFpEF) comprises approximately 50% of all&#xD;
      heart failure. The effectively therapeutic approaches for HFpEF remain limited. The&#xD;
      PARAGON-HF trial found that Angiotensin Receptor-Neprilysin Inhibition (ARNI) has potential&#xD;
      benefits for the management of HFpEF. Nevertheless, the role of ARNI in cardiac fibrosis in&#xD;
      HFpEF are still unclear. We will conduct a prospective randomized controlled trial to&#xD;
      evaluate the effect of ARNI on cardiac fibrosis in patients with HFpEF by cardiac magnetic&#xD;
      resonance (CMR). We will randomly assign 60 patients with HFpEF (NYHA II-IV) class, ejection&#xD;
      fraction ≥ 50% and elevated level of natriuretic peptides to receive sacubitril-valsartan&#xD;
      (target 100mg bid) or placebo (100mg bid). The primary endpoint is change in extracellular&#xD;
      volume [ECV] measured by CMR. The secondary endpoints were 6-minute walking distance(6-WMD),&#xD;
      KCCQ, hospitalizations for heart failure, myocardial infarction and death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular volume [ECV]</measure>
    <time_frame>Before ARNI or placebo treatment and after 3 months of continuous ANRI or palcebo treatment</time_frame>
    <description>Extracellular volume [ECV] assessment by CMR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction, hospitalization for heart failure and death</measure>
    <time_frame>After 3 months of continuous ANRI or palcebo treatment</time_frame>
    <description>myocardial infarction, hospitalization for heart failure and all-cause death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>HFpEF with ARNI treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sacubitril/valsartan (ARNI, 100mg bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (100mg bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin Receptor-Neprilysin Inhibition</intervention_name>
    <description>Sacubitril/valsartan [100 mg] bid). Continuous treatment was maintained for at least three months.</description>
    <arm_group_label>HFpEF with ARNI treatment</arm_group_label>
    <other_name>Sacubitril/valsartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo [100 mg] bid). Continuous treatment was maintained for at least three months.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated written informed consent&#xD;
&#xD;
          -  Age ≥ 45 years at time of screening&#xD;
&#xD;
          -  Preserved systolic left ventricular function, defined by left ventricular ejection&#xD;
             fraction (LVEF) ≥ 50%&#xD;
&#xD;
          -  NYHA classes II-IV&#xD;
&#xD;
          -  H2FPEF score ≥ 6 or HFA-PEFF score ≥ 5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a known history of angioedema&#xD;
&#xD;
          -  History of hypersensitivity to ARNI&#xD;
&#xD;
          -  Any prior echocardiographic measurement of LVEF &lt;45%&#xD;
&#xD;
          -  Significant congenital heart disease&#xD;
&#xD;
          -  Rheumatic valvular heart disease&#xD;
&#xD;
          -  Acute coronary syndrome, cardiac surgery, other major cardiovascular surgery&#xD;
&#xD;
          -  Probable alternative diagnoses could account for the patient's HF symptoms&#xD;
&#xD;
          -  Systolic blood pressure(BP) &gt;180 mm Hg or diastolic BP &gt;120 mm Hg at visit&#xD;
&#xD;
          -  Diastolic BP &lt;90 mm Hg at visit 1, or symptomatic hypotension&#xD;
&#xD;
          -  Patients with a cardiac pacemaker therapy device&#xD;
&#xD;
          -  eGFR &lt;30 ml/min/1.73 m2&#xD;
&#xD;
          -  Serum potassium &gt;5.2 mmol/l at visit 1&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The first affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.</citation>
    <PMID>31475794</PMID>
  </reference>
  <reference>
    <citation>Vaduganathan M, Jhund PS, Claggett BL, Packer M, Widimský J, Seferovic P, Rizkala A, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur Heart J. 2020 Jul 1;41(25):2356-2362. doi: 10.1093/eurheartj/ehaa184.</citation>
    <PMID>32221596</PMID>
  </reference>
  <reference>
    <citation>van der Meer P, Gaggin HK, Dec GW. ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. J Am Coll Cardiol. 2019 Jun 4;73(21):2756-2768. doi: 10.1016/j.jacc.2019.03.478. Review.</citation>
    <PMID>31146820</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Dongying Zhang</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

